SkinBioTherapeutics (LON:SBTX) Shares Up 21.6% – What’s Next?
by Teresa Graham · The Cerbat GemSkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s stock price rose 21.6% on Monday . The stock traded as high as GBX 7.30 and last traded at GBX 7.30. Approximately 2,591,278 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 4,836,787 shares. The stock had previously closed at GBX 6.01.
SkinBioTherapeutics Price Performance
The firm has a market cap of £21.38 million, a price-to-earnings ratio of -26.61 and a beta of 0.47. The company has a current ratio of 4.84, a quick ratio of 10.01 and a debt-to-equity ratio of 10.55. The stock’s fifty day moving average price is GBX 13.58 and its 200-day moving average price is GBX 14.91.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.